

AD _____

Award Number: DAMD17-98-1-8579

TITLE: Novel RNA- or Antibody-Based Strategies Targeting Growth
Factors in Prostate Cancer

PRINCIPAL INVESTIGATOR: Yoko Fujita-Yamaguchi, Ph.D.

CONTRACTING ORGANIZATION: The Beckman Research Institute
Duarte, California 91010-3000

REPORT DATE: September 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for public release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			Form Approved OMB No. 074-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503.				
1. AGENCY USE ONLY (Leave Blank)	2. REPORT DATE September 1999	3. REPORT TYPE AND DATES COVERED Annual (1 Sep 98 - 31 Aug 99)		
4. TITLE AND SUBTITLE Novel RNA- or Antibody-Based Strategies Targeting Growth Factors in Prostate Cancer		5. FUNDING NUMBERS DAMD17 - 98 - 1 - 8579		
6. AUTHORS Yoko Fujita-Yamaguchi, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Beckman Research Institute Duarte, California 91010-3000 E-MAIL: yyamaguchi@coh.org		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER		
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for public release; distribution unlimited		12b. DISTRIBUTION CODE		
13. ABSTRACT (Maximum 200 words) <p>RNA- or antibody-based strategies may provide novel strategies for inhibiting the expression of specific gene products that may be involved in prostate cancer cell growth and progression. Prostate cancer cells could escape hormonal control by constitutively expressing growth factors such as insulin-like growth factors (IGFs). This proposal is to test the hypothesis that IGF-II/IGF receptor signaling plays an important role in prostate cancer growth and progression. To prove the hypothesis, our newly constructed IGF-II ribozymes and single-chain antibodies against the IGF-I receptor (αIGFIR scFvs) are being used.</p> <p>Specific Aim 1 is to test our hypothesis using already available PC-3 prostate cancer cell transfectants and control cells. Effects of intracellular expression of IGF-II ribozyme or αIGFIR scFv on cell growth, anticancer-drug induced apoptosis, and tumorigenesis will be investigated in cell culture and in athymic mice.</p> <p>Specific Aim 2 is to take alternative approaches towards testing our hypothesis and developing novel gene and/or immunotherapy approaches for prostate cancer treatment.</p> <p>RNA- or antibody-based strategies targeting growth factors in prostate cancer have never been evaluated. The proposed studies should thus lay the foundation for the development of novel strategies for prostate cancer treatment.</p>				
14. SUBJECT TERMS Prostate Cancer		15. NUMBER OF PAGES 31		
		16. PRICE CODE		
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

_____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

X In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals", prepared by the Committee on Care and Use of Laboratory Animals of the Institute of Laboratory Resources, National Research Council (NIH Publication NO. 86-23, Revised 1985).

N/A for the protection of human subjects, the investigator(s) adhered to the policies of applicable Federal Law 45 CFR 46.

N/A In conducting research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

N/A In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

 9/20/99
PI Signature Date

TABLE OF CONTENTS

	<u>Page(s)</u>
FRONT COVER.....	1
REPORT DOCUMENTATION PAGE.....	2
FOREWORD.....	3
TABLE OF CONTENTS.....	4
INTRODUCTION.....	5
BODY.....	6-8
KEY RESEARCH ACCOMPLISHMENTS.....	9
REPORTABLE OUTCOME(S)	10
CONCLUSIONS.....	11
REFERENCES.....	12
APPENDICES.....	13-31
Figures 1-7	[Pages 13-20]
Reprint	[Pages 21-31]

INTRODUCTION

Blockage of IGF-II/IGF-I receptor signaling by novel RNA- or antibody-based strategies should result in inhibition of prostate cancer cell growth and progression, and also induction of programmed cell death (apoptosis). The therapeutic potential of ribozymes and single-chain antibodies that target IGF-II and IGFIR, respectively, has never been tested. Now that the first sets of IGF-II ribozyme and anti-IGFIR single chain antibody (α IGFIR scFvs) have been designed, constructed, and expressed in a prostate cancer cell line in the PI's laboratory, it is possible to test their therapeutic potential for prostate cancer. Based on the first set of experiments, alternative strategies to improve the efficacy of ribozymes and α IGFIR scFvs are being explored.

BODY

Task 1. To evaluate the effect of intracellular expression of IGF-II ribozyme and α IGFIR scFvs on cell growth, tumorigenesis, and apoptosis in cell culture and athymic mice (Months 1-24)

- **To test the efficacy of the ribozyme expression on prostate cancer cell growth and apoptosis (Months 1-12)**

We have evaluated the effect of the IGF-II ribozyme expression on PC-3 cell growth, which demonstrated that PC-3 cells expressing the ribozyme do not grow but tend to die under the serum-free or low serum conditions while PC-3 cells expressing the inactive ribozyme or vector only grew or survive. This demonstrated that IGF-II ribozymes were able to lower endogenous IGF-II mRNA and protein levels, thereby blocking IGF-II/IGFIR signaling and inhibiting cell growth, which has been published (1)(Xu *et al.*, Endocrinology, **140**, 2134-2144, 1999; see Enclosure).

We have tried to evaluate whether PC-3 cells expressing the IGF-II ribozyme are prone to apoptosis. The experiments to measure apoptosis in general, however, did not work well in our laboratory. Thus, we stopped pursuing this research direction.

- **To test the efficacy of the α IGFIR scFvs expression on prostate cancer cell growth and apoptosis (Months 1-12)**

We lost the stable PC-3 clones expressing α IGFIR scFvs such as clones 19 and 26 shown in Fig. 3 of the original proposal. We attempted to isolate new stable PC-3 clones expressing α IGFIR scFvs, but failed to do so. Thus, we switched our strategy from stable transfection to transient transfection. The experiments are now underway.

- **To purify and characterize soluble α IGFIR scFv-Fc (Months 1-6)**

Purification and characterization of α IGFIR scFv-Fc are summarized below.

Purification of α IGFIR scFv or scFv-Fc: The cell culture supernatant of ~40 ml, collected from α IGFIR scFv-Fc-expressing transfectants, clone 1F12 or 1B8, was adjusted to pH 8.0 by adding 1/20 volume of 1.0 M Tris (pH 8.0), and passed through a Protein A-Sepharose CL 4B column (1 ml column). The column was washed with 10 column volumes of 100 mM Tris-HCl buffer, pH 8.0, 10 column volumes of 10 mM Tris-HCl pH 8.0. α IGFIR scFv-Fc was eluted from the column by 100 mM glycine buffer pH 3.0, and collected in 1.5 ml conical tubes containing 1/10 volume of 1M Tris (pH 8.0).

From culture media of 1F12 (40 ml) and 1B8 (38 ml), 1.8 and 3.2 mg of α IGFIR scFv-Fc, respectively, were purified. The level of α IGFIR scFv-Fc expression was thus calculated to be 45 and 85 μ g/ml for 1F12 and 1B8, respectively. The purified α IGFIR scFv-Fc was used for biochemical and activity analyses of the engineered α IGFIR scFvs. To date, we have purified nearly 400 mg of the soluble α IGFIR scFv-Fc, which has been and will be used to characterize the effect of IGF signaling in cancer growth *in vitro* and *in vivo*.

Structural and functional analysis of α IGFIR scFv-Fc: SDS-PAGE analysis (7.5% gel) under reducing conditions revealed a single protein band of 53 kDa (Fig. 1A lanes 2 & 3), which showed immunoreactivity with anti-1H7 antibody (Fig. 1A lane 5). A single disulfide-linked protein of 120 kDa was detected by SDS-PAGE analysis (5% gel) under nonreducing conditions (Fig. 2B lane 1 & 2), indicating that α IGFIR scFv-Fc is a disulfide-linked dimer. Gel filtration showed that the dimer eluted at the expected position for the size of dimer, indicating that α IGFIR scFv-Fc does not form aggregates larger than a dimer in solution (data not shown).

First 15 N-terminal amino acids of the purified α IGFIR scFv-Fc were sequenced, which confirmed the authenticity of this recombinant antibody and the proper removal of the signal peptide. Binding constants of 1H7 and α IGFIR scFv-Fc for IGFIR determined by BIAcore were 1×10^9 and $1 \times 10^8 \text{ M}^{-1}$, respectively.

Inhibition of IGF-I or IGF-II binding to the purified IGFIR by 1H7 or α IGFIR scFv-Fc: Effects of α IGFIR mAbs and α IGFIR scFv-Fc on IGF-I and IGF-II binding to the purified IGFIR are shown in Fig. 2. α IGFIR scFv-Fc inhibited IGF-II binding to the IGFIR more potently than IGF-I binding, which showed a similar trend to the previous observation with 1H7 (2). The inhibition potency by α IGFIR scFv-Fc was 10 times less than that by 1H7, which is consistent with their binding affinity difference. A control 2C8 mAb did not inhibit IGF-I or IGF-II binding to IGFIR.

Stimulation of autophosphorylation of the purified IGFIR by α IGFIR scFv-Fc:

Autophosphorylation of the purified IGFIR was compared in the absence and presence of IGF-I, α IGFIR scFv-Fc, 1H7, and positive control poly L-lysine (PLL). Both antibodies similarly stimulated the β subunit phosphorylation (Fig. 4). Stimulation was the highest with PLL (12.8-fold) followed by IGF-I (3.8-fold), 1H7 (2.3-fold), and α IGFIR scFv-Fc (1.8-fold).

Effect of α IGFIR scFv-Fc on cell growth: The effect of extracellular addition of α IGFIR scFv-Fc or 1H7 on cell growth was determined by MTT methods using NIH3T3 cells overexpressing IGFIR. The average of four independent experiments is shown in Fig. 4. Cell growth was significantly inhibited after 4 days treatment with 10 or 100 nM 1H7 mAb (Fig. 4A) ($P < 0.05$). In contrast, α IGFIR scFv-Fc was not as effective as 1H7 in inhibiting cell growth (Fig. 4B). After 4 days treatment with α IGFIR scFv-Fc, however, cell growth appeared to be inhibited by a dose-dependent manner. The highest dose used, 1000 nM α IGFIR scFv-Fc, was required to inhibit cell growth to the level similar to that achieved by 100 nM 1H7. This difference is presumably due to the difference in their affinity for the IGFIR.

- To test the effect of the intracellular ribozyme expression on tumorigenesis and apoptosis in athymic mice (Months 6-24)

Effects of intracellular ribozyme expression on tumorigenesis have been measured using PC-3 cells expressing ribozymes, control vector, and parental PC-3 cells in athymic nude mice. After the Experiment #1, we found that R4 and R6 lost the ribozyme expression while R39 was still expressing the ribozyme.

Experiment #1: Nude mice/PC-3 Rz clones (PC-3, vector (R6), vector (R4), R39, Rz)

Experiment #2: Nude mice/PC-3 Rz clones (PC-3, vector (R6), R39, Rz)

PC-3 tumor growth from above two experiments, #1 and #2 are shown in Figs. 5 and 6, respectively.

The results repeatedly indicated that Rz-expressing PC-3 clones, especially Rz, appear to grow *in vivo* more aggressively than control vector or parental PC-3 cells. These results are contrary to those of the *in vitro* cell growth experiments in which we showed that Rz-expressing PC-3 clones do not grow well as control PC-3 cells (1). In order to investigate this unexpected result we obtained, we are collaborating with Dr. Daisy De Leon, Loma Linda University.

- **To test the effect of the intracellular α IGFIR scFvs expression on tumorigenesis and apoptosis in athymic mice (Months 6-24)**

Since we were not able to obtain stable PC-3 transfectants expressing α IGFIR scFvs to evaluate the effect of the intracellular α IGFIR scFvs expression on tumorigenesis and apoptosis, we examined the effect of extracellular addition of α IGFIR scFv-Fc on PC-3 tumor growth in athymic mice. We did not find the significant effect of extracellular addition of α IGFIR scFv-Fc on PC-3 tumor growth in athymic mice (Fig. 7) while breast cancer MCF-7 tumor growth was significantly inhibited *in vivo* under the same conditions. We reason that this difference is due to the level of IGFIR expression which influence IGF dependency of the cancer cells.

Task 2. To construct and evaluate alternative ribozymes and scFvs (Months 13-30)

- **To construct and express alternative IGF-II ribozymes (Months 13-24)**

Rz constructs have been ligated into pLNL6MoMuLV; Rz/pLNL6MoMuLV (active Rz) and M/pLNL6MoMuLV (inactive mutant Rz). Retrovirus-mediated transfer to three prostate cancer cell lines, PC-3, DU145, LNCaP, is being carried out to compare the effect of Rz expression on prostate cancer cell growth.

- **To construct and express additional α IGFIR scFvs (Months 13-30)**

α IGFIR scFv constructs have been ligated into pHaNeoIRES; α IGFIR scFv/pHaNeoIRES (soluble form) and α IGFIR scFv-ER/pHaNeoIRES (ER-retained form). Retrovirus-mediated transfer to prostate cancer cell lines is being carried out to compare the effect of scFvs expression on prostate cancer cell growth.

- **To evaluate alternative IGF-II ribozymes in cell culture (Months 18-30)**

This part has not been started.

- **To evaluate alternative IGF-II ribozymes in cell culture (Months 18-30)**

This part has not been started.

DISCUSSION

Intracellular expression of an active IGF-II ribozyme suppressed endogenous IGF-II mRNA and protein levels, and thereby inhibited prostate cancer PC-3 cell growth. This result is consistent with our hypothesis that IGF-II plays a critical role in prostate cancer cell growth.

We have thus far failed to obtain stable PC-3 cell transfectants expressing α IGFIR scFvs. In addition, inhibition of IGF-II/IGFIR signaling by intracellular expression of IGF-II ribozyme reduced endogenous IGF-II levels only to ~40% of the control levels, which resulted in cell growth inhibition. The results not only confirmed our hypothesis, but also suggested that complete inhibition of the IGF-II/IGFIR signaling cannot be achieved since this signaling is absolutely required for PC-3 cell growth.

Thus, our focus for the Year 2 will be the retrovirus-mediated transient expression of IGF-II ribozyme and α IGFIR scFvs to three prostate cancer cell lines to test the effect of IGF-II ribozyme or α IGFIR scFvs expression on cell growth.

KEY RESEARCH ACCOMPLISHMENTS

1. The effect of intracellular expression of IGF-II ribozyme on prostate cancer PC-3 cell growth was evaluated. PC-3 cells expressing the ribozyme do not grow under the serum-free or low serum conditions while PC-3 cells expressing the inactive ribozyme or vector-transfected PC-3 cells grew. This result was consistent with our hypothesis that IGF-II plays a critical role in prostate cancer cell growth.
2. We have thus far failed to obtain stable PC-3 cell transfectants expressing α IGFIR scFv. In addition, inhibition of IGF-II/IGFIR signaling by intracellular expression of IGF-II ribozyme reduced endogenous IGF-II levels only to ~40% of the control levels.

These "negative" results not only confirmed our hypothesis, but also suggested that complete inhibition of the IGF-II/IGFIR signaling cannot be achieved since this signaling is absolutely required for PC-3 cell growth.

REPORTABLE OUTCOMES

1. IGF-II ribozymes were able to lower endogenous IGF-II mRNA and protein levels, thereby blocking IGF-II/IGFIR signaling and inhibiting PC-3 cell growth, which has been published (Xu *et al.*, Endocrinology, **140**, 2134-2144, 1999; see Enclosure).

The effect of intracellular expression of IGF-II ribozyme on prostate cancer PC-3 cell growth, which is an important outcome to demonstrate the role of IGF-II on prostate cancer growth, has been supported by this award.

Stable PC-3 cell lines expressing IGF-II ribozyme as well as vector control cell lines have been developed.

CONCLUSIONS

Intracellular expression of an active IGF-II ribozyme suppressed endogenous IGF-II mRNA and protein levels, and thereby inhibited prostate cancer PC-3 cell growth. This result is consistent with our hypothesis that IGF-II plays a critical role in prostate cancer cell growth.

Inhibition of IGF-II/IGFIR signaling by intracellular expression of IGF-II ribozyme, however, reduced endogenous IGF-II levels only to ~40% of the control levels, which moderately reduced cell growth. This is reasonable since only PC-3 cell transfectants expressing IGF-II ribozyme, which are able to grow, can be achieved as stable clones.

We have been unable to obtain stable PC-3 cell transfectants expressing α IGFIR scFvs.

These "negative" results not only confirmed our hypothesis, but also suggested that complete inhibition of the IGF-II/IGFIR signaling cannot be achieved since this signaling is absolutely required for PC-3 cell growth.

Thus, our focus for the Year 2 will be the retrovirus-mediated transient expression of IGF-II ribozyme and α IGFIR scFvs to three prostate cancer cell lines to test the effect of IGF-II ribozyme or α IGFIR scFvs expression on cell growth.

REFERENCES

1. Xu, Z.-D., Oey, L., Mohan, S., Kawachi, M.H., Lee, N.-S., Rossi, J.J., and Fujita-Yamaguchi, Y. (1999) Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-II RNA *in vitro* and in prostate cancer cells. *Endocrinology*, **140**, 2134-2144.
2. Li, S.-L., Kato, J., Paz, B.I., Kasuya, J., and Fujita-Yamaguchi, Y. (1993) Two new monoclonal antibodies against the α subunit of the human insulin-like growth factor-I receptor. *Biochem. Biophys. Res. Comm.* **196**:92-98.

APPENDICES

- Figures 1 – 7
- Reprint of publication, *Endocrinology* **140**, 2134-2144




Figure 1. Purification of soluble form α IGFIR scFv-Fcs. A) SDS-PAGE under reducing conditions followed by Coomassie-staining (lanes 1-3) and immunoblotting (lanes 4 & 5) of the purified α IGFIR scFv-Fc. Shown are α IGFIR scFv-Fc purified from conditioned media of two independent stable clones, 1F12 and 1B8, as indicated. B) SDS-PAGE under nonreducing conditions, followed by Coomassie-staining of the purified α IGFIR scFv-Fc.




Figure 2. Effects of αIGFIR scFv-Fc and mAbs on ^{125}I -IGF-I (A) and ^{125}I -IGF-II (B) binding to the purified human IGF-I receptor. The binding activity is expressed as the per cent of binding in the absence of antibodies. Antibodies used are αIGFIR scFv-Fc (○), 1H7 (□), and control 2C8 (◇).




Figure 3. Effects of αIGFIR scFv-Fc and 1H7 on β subunit phosphorylation of the purified IGFIR. IGFIR was autophosphorylated in the presence of IGF-I and /or antibodies as indicated. Samples were analyzed by SDS-PAGE under reducing conditions. Shown is a phosphoimage of the gel. Fold-stimulation for the samples (lanes 2-7) was calculated by dividing the basal level phosphorylation (lane 1).



A: 1H7**B: scFv-Fc**

Figure 4. Effects of α IGFIR scFv-Fc and 1H7 on cell growth *in vitro*. NIH cells overexpressing IGFIR were cultured in DMEM supplemented with 2% FCS in the absence (◆) or presence of 10 nM (■), 100 nM (Δ), or 1000 nM (×) of 1H7 (A) or α IGFIR scFv-Fc (B).




Figure 5. Effects of intracellular expression of IGF-II ribozyme on PC-3 tumor growth *in vivo* in nude mice. Nude mice, four each of 21 day-old mice, were inoculated s.c. in the flank with 10^7 PC-3 cells or PC-3 cells expressing Rz or vector control cells. The results of Experiment #1 are shown; PC-3 (parental), R6 (vector control), R4 (vector control; not shown), R39 (Rz expressing), and Vector (Rz expressing). Tumor growth was determined twice weekly by measuring length (l) and width (w), and the tumor volume was calculated as $w^2 \times l/2$. Two mice indicated with (#) in Rz-group were sacrificed because tumors had been ulcerated.




Figure 6. Effects of intracellular expression of IGF-II ribozyme on PC-3 tumor growth *in vivo* in nude mice. Nude mice, four each of 21 day-old mice, were inoculated s.c. in the flank with 10^7 PC-3 cells or PC-3 cells expressing Rz or vector control cells. The results of Experiment #2 are shown. PC-3, R6, R39, and Vector, correspond to parental cells, vector control, and two Rz-expressing cells, respectively. Four mice and three mice indicated with (†) in PC3 cell-group and Rz-group, respectively, were sacrificed because tumors had been ulcerated.




Figure 7. Effects of α IGFIR scFv-Fc administration on PC-3 tumor growth *in vivo* in nude mice. Three week old athymic mice were inoculated in the flank S.C. with 2×10^6 PC-3 cells on Day 0. On Day 5, α IGFIR scFv-Fc treatment started; intraperitoneal injections of α IGFIR scFv-Fc into 6 mice each (0.5 mg per mouse) twice weekly while control mice received PBS. Tumor growth was measured as described above.

Hammerhead Ribozyme-Mediated Cleavage of the Human Insulin-Like Growth Factor-II Ribonucleic Acid *in Vitro* and in Prostate Cancer Cells*

ZHAO-DONG XU, LILY OEY, SUBBURAMAN MOHAN, MARK H. KAWACHI,
NAN-SOOK LEE, JOHN J. ROSSI, AND YOKO FUJITA-YAMAGUCHI

Department of Molecular Biology (Z.D.X., L.O., N.-S.L., J.J.R., Y.F.-Y.) Beckman Research Institute of the City of Hope and Department of Urology (L.O., M.H.K.), City of Hope Medical Center, Duarte, California 91010; and Department of Biochemistry, Physiology, and Medicine (S.M.), Loma Linda University, Jerry L. Pettis Veterans Affairs Medical Center, Loma Linda, California 92357

ABSTRACT

Insulin-like growth factor (IGF)-II plays an important role in fetal growth and development. IGFs are potent mitogens for a variety of cancer cells. A paracrine/autocrine role of IGF-II in the growth of breast and prostate cancer cells has been suggested. To test the role of IGF-II in cancer cell growth, hammerhead ribozymes targeted to human IGF-II RNA were constructed. Single (R)- and double (RR)-ribozymes were catalytically active *in vitro* whereas mutant ribozymes (M or MM) did not cleave IGF-II RNA. RR was more active than R. In human prostate cancer PC-3 cells, both R and RR similarly

suppressed IGF-II messenger RNA (mRNA) levels (~40%) compared with the level in parental or M-expressing PC-3 cells. Polymerase II and III promoter-driven R similarly suppressed IGF-II mRNA levels. Suppression of IGF-II mRNA levels by R was associated with suppression of IGF-II protein levels. R- (or RR-) expressing PC-3 cells did not grow under serum-starved conditions and showed prolonged doubling times in the presence of 10% FCS compared with those of parental or M-expressing cells. These results substantiated that IGF-II plays a critical role in prostate cancer cell growth. (*Endocrinology* 140: 2134–2144, 1999)

CANCER arises as a result of a series of molecular alterations in normal cells including up-regulation of growth factors that could facilitate uncontrolled cell growth. Insulin-like growth factor (IGF)-I and -II are important mitogens for a variety of cancer cells (1). The mitogenic actions of both IGF-I and -II are mediated via the IGF-I receptor (2–4). IGF-II also binds to the IGF-II/mannose-6 phosphate receptor and insulin receptor with high affinity while IGF-I binds to these receptors with low affinity. In addition, IGF-binding proteins bind IGFs with high affinity (5) and modulate IGF actions in both a positive and negative manner. Thus, the activity of IGFs in the local tissues depend, not only on the amount of IGFs produced, but also on the type and amount of IGF system components present.

IGF-II is a 7.5-kDa single-chain polypeptide of 67 amino acid residues, which is processed from its precursor (6). Previous studies suggested that an incompletely processed form of 15-kDa IGF-II is expressed more abundantly than the 7.5-kDa form in many cancers (1, 7–9). The 15-kDa form of human IGF-II was shown to have a mitogenic potency greater than that of 7.5 kDa (10). We showed that of 36 prostate, 17 breast, 10 bladder cancers, and 9 paraganglioma

tissues examined, IGF-II was expressed in more than 50% of prostate, breast, and bladder tumors, and in 100% of paraganglioma tumors (9). Greater expression of the 15-kDa IGF-II relative to the 7.5-kDa IGF-II form was clearly demonstrated in all six prostate cancers and in one of the two breast and two of the four bladder cancers examined (9). The results are consistent with the hypothesis that the 15-kDa form of IGF-II expressed in cancerous cells contributes to autocrine cancer cell growth *in vivo*.

Evidence is accumulating that an enhanced IGF/IGF-I receptor (IGFIR) signaling leads to increased cancer cell proliferation and tumorigenesis as well as antiapoptotic effects (11, 12). For example, it has been demonstrated in experimental systems that overexpression of human IGFIR promotes ligand-induced neoplastic transformation (13) and tumorigenesis (14) in the presence of an active protein tyrosine kinase. An important role of IGFIR in mediating c-Myc-induced apoptosis of fibroblasts in low serum medium was first reported (15). Since then, a series of studies supporting the antiapoptotic role of IGFIR in cancer cells have been published (16–18). In brief, reduction of the number of IGFIR by introduction of antisense IGFIR cDNA caused extensive apoptosis *in vivo* in several transplantable human or rodent tumors (16).

In the case of prostate cancer, it was originally reported that IGF-I is responsible for autocrine growth of human prostate cancer cell lines including androgen-dependent LNCaP as well as hormone-independent DU145 and PC-3 cells (19). We and others more recently showed that IGF-II, but not IGF-I, is produced in those established human prostate cancer cell lines and suggested an autocrine regulation

Received August 27, 1998.

Address all correspondence and requests for reprints to: Yoko Fujita-Yamaguchi, Ph.D., Department of Molecular Biology, Beckman Research Institute of the City of Hope, 1450 East Duarte Road, Duarte, California 91010. E-mail: yyamaguchi@coh.org.

* Supported in part by NIH Grants, CA-65767, AI-38592, and AI-29329 and DOD Grant PC-970432. This work was a part of Ph.D. dissertation of Loma Linda University graduate school for Zhao-Dong Xu, and has been presented at 80th Annual Meeting of The Endocrine Society, New Orleans, Louisiana, June 24–27, 1998.

IGF-II AND CELL GROWTH MODULATION BY RIBOZYMES

of DU145 and PC-3 cell growth by IGF-II (20–22). Furthermore, recent studies using *in situ* hybridization and immunohistochemistry indicated that epithelial cells rather than stromal cells in prostate tumors express IGF-II *in vivo* (9, 23). These data provided the basis for using prostate cancer as a model to test the hypothesis that cancer cell growth may be regulated by IGF-II in an autocrine manner.

Blockage of IGF-II/IGFIR signaling and subsequent effects on cell growth, transformation, and tumorigenicity have been reported. Examples of strategies to block IGF-II/IGFIR signaling include 1) inhibition of IGF-II expression by antisense oligonucleotides or RNAs (24–26); 2) inhibition of IGFIR expression by antisense oligonucleotides or RNAs (19, 27–28); 3) blockage of IGFIR by IGFIR monoclonal antibody such as α IR-3 (29, 30); and 4) blockage of IGF-mediated growth by IGF-binding proteins (20, 31). In addition, a number of anticancer drug agents have been shown to work, at least in part, by suppression of IGFIR action. For instance, suramin administration to breast, lung, and prostate cancer patients significantly reduced IGF-I and -II serum levels (32). Similarly, the antiestrogen tamoxifen has a powerful cytostatic effect in breast cancer cells, which in part is due to its inhibitory effect on the IGF-I/IGFIR axis (33).


Ribozymes (RZs) are RNA enzymes that specifically cleave their respective target RNAs, thereby inhibiting the expression of specific gene products. Hammerhead-type RZs work in *cis* (intramolecularly) in nature, but separation of *cis*-acting RZs into two RNA fragments can convert them into *trans*-acting RNAs capable of site-specific cleavage of substrate RNAs. In the last 15 yr, RZs have progressed from an intriguing subject of scientific study to therapeutic agents for the potential treatment of both acquired and inherited diseases (34). It is becoming increasingly evident that RZs can serve the dual function of a tool to elucidate the functional roles of many gene products as well as therapeutic agents designed to functionally destroy deleterious RNAs. Suppression of IGF-II expression by IGF-II-specific RZs in cells has never been reported. We thus constructed catalytically active IGF-II RZs and expressed them intracellularly in human prostate cancer PC-3 cells.

Materials and Methods

Design and construction of IGF-II RZs

Two hammerhead RZs were designed and constructed to be complementary to the sequence near the translation initiation site of human prepro-IGF-II mRNA at nucleotides 16–30 and 16–46, respectively (Fig. 1). As controls, activity of RZ was inactivated by introducing a point mutation of G to A in the catalytic core as shown in Fig. 1. Template DNAs for RZs and mutant RZs were prepared by filling in the opposite strands of two overlapping oligonucleotides by PCR. The oligonucleotides used for construction of the single ribozyme were 5'-ACGCGTCGACGAGCATCCT(A/G)ATGAGTCCGTGAGG-3' (34 bases) and 5'-GCTCTAGAGCGGGGAAGTTTCGTCCTACGGACTC-3' (35 bases), which contained restriction enzyme *Sall* and *XbaI* sites, respectively. The primers for the double RZs were 5'-ACGCGTCGACAGAGGTCT(A/G)ATGAGTCCGTGAGGACGAAAGAAGCACCAGCAT-3' (53 bases) and 5'-GCTCTAGAGCGGGGAAGTTTCGTCCTACGGACTCAT(C/T)AGGATGCTGCTT-3' (52 bases), which contained restriction enzyme *Sall* and *XbaI* sites, respectively. For both single and double RZs, the sequences that are complementary are underlined. Note that the position indicated as (/) represents equal ratios of both nucleotides incorporated to generate both active and inactive (mutant) RZ at the same time. The template DNAs for single and double RZ were prepared by five cycles of PCR

Single ribozyme



Double ribozyme




FIG. 1. Structure of the hammerhead RZ and target human IGF-II RNA. Secondary structures of single and double RZs and IGF-II substrate RNA are illustrated. Cleavage of the IGF-II substrate occurs at 3' of the GUC or CUC as indicated with ↓. To produce an inactivated RZ, a highly conserved base, G5, in the catalytic domain, which is required for cleavage, was mutated to A as shown (G → A).

of 94 C for 1 min, 37 C for 1.5 min, and 72 C for 1.5 min, and five cycles of PCR of 94 C for 1 min, 33 C for 1.5 min, and 72 C for 0.5 min, respectively. After the PCR, the quality of PCR products was examined by PAGE. The PCR products were cleaned up, digested with *Sall* and *XbaI*, and subcloned into the *Sall/XbaI* sites of pTZU6 + 27 vector, which contained the human U6 promoter and pUC19 multiple cloning site (36). After the ligation reaction was carried out, the ligation products were electroporated into *Escherichia coli* XL-1 blue cells. The bacteria were plated on the LB agar containing ampicillin, X-gal, and isopropyl- β -D-thiogalactopyranoside. Plasmids were prepared from white colonies, and colonies containing the correct inserts were identified by *Sall/XbaI* digestion and gel electrophoresis. To confirm authenticity of the RZs, plasmid DNAs were prepared and subjected to Southern blot analysis and DNA sequencing. Clones expressing single RZ (R) and its mutant (M, an inactive RZ in which a point mutation of G5 to A is introduced), and double RZ (RR), its mutant (MM), and double RZ with one mutant, RM or MR, were isolated. These plasmids, pTZU6+27/RZ, were used for both *in vitro* transcription of RZ as well as RNA polymerase (pol) III-driven expression of the RZ in mammalian cells.

Overlapping oligonucleotides that contained *HindIII* or *XbaI* sites were used to produce R or M, which was subcloned into *HindIII/XbaI* sites of pcDNA3 (pcDNA3/RZ). The primers used were; 5'-GCTCTAGAGCGGGGAAGTTTCGTCCTACGGACTC-3' and 5'-CCCAAGCTTGGGCAGCATCCT(A/G)ATGAGTCCGTGAGG-3', in which complementary sequences are underlined. The template DNAs for R or M were prepared as described for pTZU6 + 27.

Subcloning of IGF-II substrate

To test the *in vitro* cleavage efficiencies of the RZs, a substrate human IGF-II RNA [–6 to +74, 80 nucleotides (nt)] was prepared by subcloning

IGF-II AND CELL GROWTH MODULATION BY RIBOZYMES

Endo • 1999
Vol 140 • No 5

a small fragment of IGF-II cDNA into pBluescriptII KS(+) (Stratagene, San Diego, CA). A DNA template for the IGF-II RNA was prepared by PCR from the full-length IGF-II cDNA (9). The primers used for the PCR were: 5'-CGGAATTCGACACCAATGGGAATCCC-3' and 5'-CGG-GATCCCGGCAGGC AGCAATGCAGCAGCA3'-, which contained a restriction enzyme site, *Bam*HI and *Eco*RI, respectively. PCR was performed as follows: 95 C for 3 min, and then 30-cycle amplification of 95 C for 1 min (denaturing), 55 C for 1 min (annealing), and 72 C for 1 min (extension).

The PCR product, digested with *Bam*HI and *Eco*RI, was ligated into pBluescript KS. Transformation of the ligation mixture was achieved by electroporation. Briefly, 3 μ l of the ligation mixture were electroporated into *E. coli* XL1 blue cells. After LB was added, the bacteria were incubated at 37 C for 1 h to allow the antibiotic-gene express, and then plated on LB/1.5% agar containing 100 μ g/ml Ampicillin, which had been layered with 100 μ l of 0.05% X-gal and 75 mM IPTG, and grown at 37 C overnight. Plasmids were prepared from white colonies and their inserts were examined by *Bam*HI/*Eco*RI double digestion and gel electrophoresis. Colonies containing the right-size insert were selected. To confirm the authenticity of the IGF-II substrate sequence, plasmid DNAs were subjected to DNA sequencing.

Preparation of IGF-II mRNA substrate by *in vitro* transcription

The plasmids that contained the IGF-II substrate (-6 to +74) and the full-length IGF-II were linearized by *Bam*HI digestion and used as templates for *in vitro* transcription. Transcription reactions were carried out at 37 C for 1 h in 40 mM Tris-HCl buffer, pH 7.9, containing ~0.2 μ g DNA template, 0.5 U/ μ l of T3 RNA pol, 20 mM MgCl₂, 10 mM NaCl, 10 mM dithiothreitol, 0.5 mM each of ATP, GTP, and uridine triphosphate, 0.05 mM cytidine triphosphate (CTP), 10 μ Ci of [α -³²P]CTP, and 1 U/ μ l of RNasin (Promega Corp., Madison, WI). After transcription, the RNAs were treated with RNase-free DNase I for 15 min and purified by electrophoresis in a 6% denaturing polyacrylamide gel for 1 h at 200 V. Before purification, a small aliquot of RNAs was removed to use for calculation of the specific activity. After electrophoresis, the gel was exposed to a Kodak XRP film (Eastman Kodak Co., Rochester, NY) for 1 min and the film was developed. The region of the gel containing the desired RNA band was excised and crushed into fine pieces. The IGF-II substrate RNA was eluted in an elution buffer overnight. The aqueous phase was removed and mixed with phenol-chloroform-isoamyl alcohol (25:24:1) to extract the RNA. The substrate RNA was precipitated with ethanol, redissolved in 20 μ l diethyl pyrocarbonate-treated H₂O, and stored at -75 C.

In vitro transcription of RZs

The pTZU6+27/RZ plasmids were linearized by *Xba*I digestion and used as templates for transcription of IGF-II RZ as described for substrate RNA preparation with two exceptions: only a trace amount of the radioisotope was used and T7 RNA pol was used instead of T3 RNA pol.

In vitro RZ cleavage assays

RZ assays were performed according to the methods previously described (37, 38). Briefly, RZs and substrate were heated independently for 1 min at 90 C in 10 μ l of water. After cooling to 25 C, the reaction buffer was added to a final concentration of 10 mM MgCl₂, 140 mM KCl, and 50 mM Tris-HCl, pH 7.5. RZs and substrate were then combined and incubated at 37 C. The reaction was stopped by adding an equal volume of stop solution (0.5% of SDS/25 mM EDTA) and then 100 μ l of phenol. The aqueous phase was brought to 100 μ l. After vortexing, the aqueous phase was removed and the RNAs were precipitated with ethanol. The RNAs were analyzed by 6% polyacrylamide/8 M urea gel electrophoresis. Radioactive bands were visualized by autoradiography and quantitated by a PhosphorImager (Molecular Dynamics, Inc.).

The single turnover experiments using RZ excess over substrate were carried out to determine the first-order rate constant for cleavage of the substrate (39). The initial cleavage velocities under single-turnover conditions were determined at a constant substrate concentration of 1 nM and varying RZ concentrations. Reaction mixtures (10 μ l) containing 0, 2.5, 5, 10, 20, 30, and 40 nM RZ and the substrate RNA (at a final

concentration of 1 nM) were incubated at 37 C for 2 h. The reaction was stopped by the addition of 10 μ l of the stop solution and analyzed by PAGE as described above. K_{cat}/K_m values were obtained by plotting the remaining fraction of the ³²P-labeled substrate RNA (Frac S) against the ribozyme concentration ([RE]) according to the following equation $k = -\ln(\text{FracS})/t = [\text{RE}] \times k_{cat}/K_m$ where k is the observed reaction rate and t is the reaction time of 2 h.

Cell culture and transfections

Human prostate cancer PC-3 cells were transfected with pTZU6+27/RZ or pcDNA3/RZ. The calcium-phosphate precipitation method was used to cotransfect PC-3 cells with pTZU6+27/RZ expression and neo vectors (40). Briefly, 24 h before transfection, exponentially growing cells were harvested by trypsinization and replated into 90-mm tissue culture dishes. Ten milliliters of RPMI 1640 medium with 10% FCS were added, and cells were incubated overnight at 37 C in a humidified incubator in an atmosphere to 5% CO₂. To those cells, were added 0.5 ml of 0.25 M CaCl₂ containing 18 μ g of superhelical plasmid RZ DNA, 2 μ g neo Vector DNA, and 0.5 ml of 2 \times PBS-buffered saline. The cells were incubated for 15 min at room temperature. RPMI 1640 medium with 10% FCS was added dropwise to the cells in the dishes, which were gently swirled. The cells were incubated for 16 h at 37 C in a humidified incubator in an atmosphere of 3% CO₂. The medium was removed by aspiration, and cells were rinsed twice with medium. Ten milliliters of fresh medium were added, and cells were incubated for 24 h at 37 C in a humidified incubator in an atmosphere of 5% CO₂. After 24 h incubation in nonselective medium to allow expression of the transferred genes to occur, the cells were trypsinized and replated in medium containing 600 μ g/ml of G418. The medium was changed every 3 days for 4 weeks to remove the debris of dead cells and to allow colonies of G418-resistant cells to grow.

For the RNA pol II-driven RZ expression system, PC-3 cells were transfected by electroporation. Cells were grown to 70% confluence, trypsinized for 2 min, centrifuged in the table-top centrifuge, and resuspended in PBS buffer at a cell density of 5×10^6 cells per ml. This suspension was preincubated with 5–20 μ g of DNA in 800 μ l of PBS buffer on ice for 10 min with mixing, transferred to a cuvette, and immediately pulsed with the following settings: capacitance, 800 μ F; resistance (R4), R4 (72 ohm); and charging voltage, 350 V. A 4-mm gap chamber was used in a BTX electroporator (San Diego, CA). After pulsing, the cells were left in ice for 10 min, transferred into the Petri dish, and cultured in the medium containing 600 μ g/ml of G418 for at least 1 month.

Detection of IGF-II RZs expressed in PC-3 cells

RZ expression in G418-resistant clones was confirmed by RT-PCR. A set of primers for detection of RZ prepared were 5'-primer, 5'-TCGCTTCG-CAGACGTCGAC-3', containing a sequence corresponding to the junction between U6 promoter and the RZ, and 3'-primer, 5'-GGGAAGTT-TCGTCCTCACGGA-3', containing a sequence of the catalytic stem underlined. RT reaction was performed at 37 C for 45 min by mixing 4 μ g of total RNA from the PC-3 transformants with 10 pmol of the 3'-primer in 50 mM Tris-HCl, pH 7.5, containing 10 mM dithiothreitol, 75 mM KCl, 3 mM MgCl₂, 1 mM of each deoxynucleoside triphosphate, 800 U of Moloney murine leukemia virus reverse transcriptase, and 20 U of RNasin. RT reaction products, equivalent to 1 μ g of total RNA from each clone, were processed through 30 cycles of PCR with denaturation at 94 C for 1 min, annealing at 47 C for 2 min, and synthesis at 72 C for 3 min, in a final volume of 20 μ l. One half of the reaction product was analyzed in 2% agarose gel, stained with EtBr, and blotted onto a nylon membrane. The blot was hybridized with a specific ³²P-labeled oligonucleotide probe, 5'-TGCTC GTAGGACTACTCA-3' (underline and **bold** indicate the complementary sequence to the catalytic stem and the position mutated in M, respectively) at 54 C for 16 h in 6 \times SSC, 5 \times Denhardt's solution, 1% SDS, and 100 μ g/ml herring-sperm DNA. The membrane was washed three times in 2 \times SSC and 0.1% SDS for 30 min at 51 C. The bands hybridized with the ribozyme-specific probe were visualized by autoradiography. For detection of RZ in pcDNA3/RZ clones, RT-PCR was performed under the same conditions as above using 5'-primer, 5'-CCCACTGCTTACTGGCTATCGA-3', and 3'-primer, 5'-GGACAGTGGGAGTGGCACCTTC-3'.

IGF-II AND CELL GROWTH MODULATION BY RIBOZYMES

Quantitation of IGF-II mRNA levels in PC-3 cells by quantitative competitive (QC)-PCR

The 5'- and 3'-primers used to detect RZ-mediated cleavage of IGF-II RNA in cells were 5'-CCAGCACCAATGGGAAT CCAATGGGGAAG-3' (-10 to +21) and 5'-GTATCTGGGGAAGTTGTCCGGAAGCAC GGTC-3' (+294 to +324), respectively. pBluescript KS/IGF2, pBluescriptII KS(+) (Stratagene, La Jolla, CA) containing approximately 1 kb *EcoRI* fragment encoding the human precursor IGF-II (911-2067 nt) (9) was used to generate a new plasmid that encodes a competitor IGF-II sequence. Detailed methods will be published elsewhere (Xu, Z.-D., R. Mineo, S.-J. Liang, and Y. Fujita-Yamaguchi, manuscript in preparation). Briefly, a 110-bp *Sall/SalI* fragment was inserted into the IGF-II sequence between the PCR primers so that when the competitor IGF-II RNA was transcribed, it would provide a template for a PCR product that is 110 bp longer than that derived from the authentic IGF-II mRNA. In the presence of the competitor RNA, a 444-bp band, which was therefore produced in addition to the 334-bp band derived from an endogenous IGF-II RNA.

Conditioned medium

PC-3 cells and transfectants were seeded in 25-cm² flasks in the regular medium. The next day, cells were washed with PBS three times and grown for 2 days in 4 ml of RPMI 1640 containing 0.1% BSA. Condition media were collected and analyzed for IGF-II and -I as previously described (22). At the time of conditioned medium collection, cell numbers were determined with a hemocytometer, and the IGF-II protein level was expressed as nanograms/ml/10⁵ cells.

Determination of cell proliferation

Cell growth was determined by the 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method, which measures mitochondrial dehydrogenase activity that is active only in living cells. Cells (10⁴ cells per well) were plated in 96-well plates containing 100 μ l of medium and cultured 37 C for 4 days. At days 1, 2, 3, and 4, 20 μ l of 0.5% MTT were added to the wells in triplicate. After incubation at 37 C for 4 h, the medium was removed and 100 μ l of isopropyl alcohol supplemented with 0.05 N HCl were added. The color developed was quantitated by measuring absorbance at 540 nm.

Doubling times of parental PC-3 cells and transfectants were determined by time-lapse microscopy. Approximately 10⁵ cells of each clone were seeded in medium supplemented by 10% FCS in a T-25 flask and incubated at 37 C overnight. The flasks were placed under a phase contrast microscope (Nikon, Melville, NY) in a warm room. A good view of isolated cells was selected and video-recorded for 4 days. Doubling time for each clone was averaged from those of five to eight cell divisions.

Results***In vitro* RZ cleavage reactions**

Catalytic activity of the RZs constructed was examined using the shorter IGF-II RNA (-6 to +74) as a substrate unless otherwise stated.

Time course. The substrate, 7.7 nM, was incubated with 12.3 nM RZ, R or M, at 37 C for 10 to 210 min (substrate-RZ ratio of 0.6:1). As shown in Fig. 2, only the active RZ cleaved the substrate in a time-dependent manner. After incubation for 210 min, all the substrate was apparently digested by R.

Substrate-RZ ratio. RZ cleavage reactions were carried out under different substrate-RZ ratio conditions. After incubation at 37 C for 210 min, more than 80% of the substrate was cleaved by single RZ, R, at the substrate-RZ ratio of 1.2 or 0.6. In contrast, percent cleavage was markedly reduced at the substrate-excess condition.




FIG. 2. Time course of RZ cleavage reaction by single RZs *in vitro*. Both RZs and substrate were ³²P labeled. A substrate-RZ ratio of 0.6:1 was incubated at 37 C for indicated time, 0-210 min. After cleavage reactions, RZ, substrate, and products were separated by 6% polyacrylamide/8 M urea gel electrophoresis. Nucleotide (nt) sizes of ribozymes, substrate, and products contain additional 5'-sequences derived from the vectors (see Figs. 1 and 3C for schematic illustrations). Note that the free substrate concentration after incubation for 3 h with M (lane 11) seems to become lower than the substrate only (lane 1), probably due to formation of a stable substrate/M RZ complex, which is resistant to denaturation conditions used in these studies.

***In vitro* cleavage reactions of single and double RZs.** RZ activities of single RZ (R), double RZ (RR), its mutant (MM), and double RZs with one mutant (RM and MR) were analyzed. Figure 3A demonstrates that *in vitro* cleavage reactions of both single and double RZs produced the expected sizes of cleavage products as illustrated in Fig. 3C. Mutant double RZ (MM) did not cleave the substrate RNA at all. To compare relative cleavage efficiencies among various RZ constructs, the intensity of the product, either P1 or P1', was quantitated. Figure 3B clearly indicates that R and RM are equally active whereas MR is less effective in cleaving the substrate IGF-II RNA than RM or R. The double RZ, RR, appeared the most active RZ of the four RZs that we constructed to target IGF-II RNA.

Comparison of RZ cleavage reactions by single and double RZs. Since the results of *in vitro* cleavage reactions suggested that RR is more active than R (Fig. 3), catalytic efficiencies of single and double RZs were further compared.

Kinetic analysis for the two RZs, R and RR, were performed under single-turnover conditions using the short IGF-II RNA substrate. The results summarized in Fig. 4 revealed $K_{cat}/K_m = 1546$ and $4772 \text{ M}^{-1}\text{s}^{-1}$, respectively. This indicates that the double RZ is approximately 3-fold more efficient in cleaving the substrate IGF-II RNA than the single RZ *in vitro* ($P < 0.05$).

The catalytic efficiencies of single and double RZs were also examined using the precursor IGF-II RNA (1157 nt) as a substrate. Both RZs cleaved the IGF-II RNA substrate after incubation for 16 h (Fig. 5A, lanes 11 and 12). The time course

IGF-II AND CELL GROWTH MODULATION BY RIBOZYMES

Endo • 1999
Vol 140 • No 5




FIG. 3. Comparison of RZ cleavage reaction by single and double RZs *in vitro*. A, Autoradiogram. Cleavage reactions by single RZ (R), double RZ (RR), its mutant (MM), and double RZs with one mutant, RM or MR, were compared. Both RZs and substrate were ^{32}P labeled. Note that RZs were ^{32}P labeled with only trace amounts of radioactivity while the substrate was fully ^{32}P labeled. The differing intensities of RZs are due to differences in the levels of radioactivity incorporated during *in vitro* transcription of template encoding different RZ constructs. RZ reactions were carried out at 37 C for 210 min at a substrate concentration of 5 nM in the presence of 1 or 5 nM RZ (R, RM, MR, RR, or MM). After cleavage reactions, RZ, substrate, and products were separated by 6% polyacrylamide/8 M urea gel electrophoresis. Nucleotide (nt) sizes of the RZ, substrate, and products are indicated. B, Relative intensity of the RZ product, P1 or P1'. Cleavage efficiencies of the RZs shown in lanes 1–8 in panel A were determined by quantitating the intensity of the products, P1 or P1'. C, Schematic illustration of IGF-II RNA substrate and RZ cleavage sites. The IGF-II substrate and RZ cleavage sites are presented schematically to show nt sizes of the products derived from each RZ or inactive RZ. An additional 5'-sequence which is attached to the substrate is shown as ~~~~~.




FIG. 4. Comparison of single and double RZs *in vitro* by single-turnover experiments. Single turnover experiments with RZ in excess over substrate were carried out and $K_{\text{cat}}/K_{\text{m}}$ values were calculated as described in *Materials and Methods*. In Exps 1 and 2, R and RR were assayed in parallel.

experiment, however, revealed that during the first 3 h of incubation, RR cleaved the substrate in a time-dependent manner whereas R did not appear significantly to cleave the

substrate (Figs. 5A, lanes 1–8, and Fig. 5B). This result is consistent with that of the kinetic analysis that indicated that RR is more active than R *in vitro*.

IGF-II AND CELL GROWTH MODULATION BY RIBOZYMES




Fig. 5. RZ cleavage reaction by single and double RZs *in vitro* using the precursor IGF-II RNA as a substrate. A, Autoradiogram. Prepro-IGF-II RNA (1157 nt) was synthesized from BluescriptII KS encoding the prepro-IGF-II cDNA. Both RZs and substrate were ^{32}P labeled. RZ reactions were carried out 37 C for 1–16 h at a substrate concentration of 15 nM with 1.2 mM single or double RZ. The results of two independent experiments are shown; lanes 1–8 and lanes 9–14 are from Exp 1 and 2, respectively. B, Relative intensity of the RZ products. Cleavage reaction by RR was shown as average of P1 and P2 produced after incubation of 1, 2, and 3 h. C, Schematic illustration of IGF-II RNA substrate and RZ products. RZ cleavage sites and expected products are schematically presented.

Intracellular cleavage of IGF-II mRNA by RZs

Intracellular activity of the RZs was determined in PC-3 cells that were stably expressing RZs. Two expression systems that use RNA pol III and II were used in this study. While RNA pol II expression systems have been developed for years and widely used for the expression of proteins, RNA pol III expression systems have been suggested to be advantageous for stable, high steady-state expression of short chimeric RNAs since RNA pol III-driven chimeric transcripts are more abundant than poly(A)⁺ RNAs in mammalian cells (41).

Stable expression of RZs in PC-3 cells driven by RNA Pol III promoter (pTZU6+27 vector).

Detection of RZ mRNA in PC-3 cell transfectants. Expression of R, M, and RR in four, two, and two transfectants, respectively, was confirmed by EtBr-stained agarose gel electrophoresis of RT-PCR products prepared from DNase I-treated RNA (data not shown). No PCR amplification was made when PCR was performed from the corresponding RNA preparations without RT (data not shown). RT-PCR products

derived from single and double RZs migrated at the same positions as PCR controls for R and RR, respectively, prepared from the plasmids encoding R and RR (data not shown). The authenticity of R, M, and RR was confirmed by Southern blot analysis using an oligonucleotide probe complementary to the R sequence (data not shown). The mutant RZ did not hybridize with the R-specific probe at 54 C due to a one-base mismatch in the probe sequence.

Quantitation of IGF-II mRNA levels in PC-3 cell transfectants. IGF-II mRNA levels in parental and transfected PC-3 cells were determined by QC-PCR using a competitive IGF-II RNA as a control (Fig. 6A). Endogenous IGF-II mRNA levels in PC-3 cells expressing R or RR were suppressed by 62% or 68%, on average, compared with that of parental PC-3 cells, whereas cells expressing M had little effect (12% suppressed) on the IGF-II mRNA levels (Fig. 6, A and B) as determined by quantitative RT-PCR.

Effect of RZ expression on PC-3 cell growth. The effect of intracellular expression of RZs and the subsequent reduction of IGF-II mRNA and protein levels on cell growth was eval-




FIG. 6. PC-3 transfectants expressing single (R), double (RR) or inactive single (M) RZ under the control of Pol III promoter. A, Endogenous IGF-II mRNA levels as determined by QC-PCR. Quantitative RT-PCR was performed using IGF-II-specific primers and 1 μ g of total RNA prepared from parental PC-3 cells (lane 3) and transfectants (lanes 4–11) in the presence of a competitor IGF-II RNA (110 bp longer than the authentic IGF-II mRNA). Lanes 1 and 2 show PCR products from control IGF-II and PC-3 RNA, respectively. B, Endogenous IGF-II mRNA levels in parental PC-3 cells and R-, RR-, or M-expressing PC-3 cells. Endogenous IGF-II mRNA was expressed as the ratio to control RNA, which is further normalized by 18S ribosomal levels shown in panel A.

TABLE 1. Effect of RZ expression on PC-3 cell growth

	Relative cell growth after 2 days in SFM (mean \pm SE) ^a
Parental PC-3 cells	1.23 \pm 0.02 (n = 2)
R-expressing PC-3 cells	0.58 \pm 0.13 (n = 5) ^b
RR-expressing PC-3 cells	0.4 (n = 1)
M-expressing PC-3 cells	1.61 \pm 0.33 (n = 2)

PC-3 cells and transfectants were plated in 24-well plates (1.3 \times 10⁴ cells per well), and cell numbers were counted after 2 day-culture in serum-free medium. Cell growth is expressed as a ratio of the cell number at day 2 to the original cell number seeded.

^a The relative cell growth values are mean values of those of independently isolated stable clones. Numbers of clonally selected transfectants are indicated in parentheses. For parental PC-3 cells, n = 2 means two independent measurements of the cell line.

^b Significantly different ($P < 0.01$) by Newman-Keuls post hoc test compared with parental PC-3 cells.

uated under serum-free conditions. Parental PC-3 and transfectants were grown in serum-free medium (SFM) for 2 days. While cell numbers of parental PC-3 cells or M-expressing cells increased, those of R- or RR-expressing cells decreased (Table 1), indicating that catalytically active RZ expression is inhibitory for PC-3 cell growth. These results suggest that cleavage of IGF-II mRNA by R or RR, but not the potential antisense effect of M *per se*, is required for inhibition of PC-3 cell growth.

Stable expression of RZs in PC-3 cells driven by RNA Pol II (pcDNA vector). While the transcripts expressed by the RNA pol III U6 + 27 system are nuclear (36), capped, polyadenylated RNA pol II transcripts are more likely to direct RZ transcripts to the same intracellular compartment as the targeted IGF-II mRNA in the cytoplasm. To compare RZ activity under the control of RNA pol II promoter, PC-3 cells were transfected with pcDNA3/RZ.

Detection of RZ mRNA in PC-3 cell transfectants. Of 10 transfectants examined, expression of R was confirmed in 4 independent clones by RT-PCR (Fig. 7A). EtBr-stained agarose

gel electrophoresis of the RT-PCR product also identified six G418-resistant clones that do not express R. They were used as vector-control cells below.


Measurements of IGF-II mRNA and protein levels in PC-3 cell transfectants. IGF-II mRNA levels in parental and transfected cells were determined by QC-PCR (Fig. 7B). Endogenous IGF-II mRNA levels for parental, R-expressing, and vector-transfected PC-3 cells were 0.2 (n = 1), 0.045 \pm 0.005 (n = 4), and 0.122 \pm 0.018 (n = 6), respectively. Endogenous IGF-II mRNA levels in R-expressing PC-3 cells were thus reduced to approximately 40% level when compared with those of six transfectants that do not express R (vector-control), and to about 20% level when compared with that of parental PC-3 cells. In parallel to the IGF-II mRNA levels, IGF-II protein levels secreted into conditioned media by R-expressing PC-3 cells were significantly lower than those of parental or vector clones, while that of the vector-transfected cells was modestly reduced (Table 2)¹.

Effect of RZ expression on PC-3 cell growth as measured by the MTT method. The growth of parental PC-3 cells and the vector- or R-transfectants, shown in Fig. 7, were analyzed in SFM (Fig. 8A) or in the presence of 2% FCS (Fig. 8B). The results clearly demonstrate that PC-3 cells expressing the IGF-II RZ do not grow well under serum-free or 2% FCS conditions. The results are similar to the observation we had for R- or RR-expressing PC-3 cells under the control of RNA pol III promoter. Since the R-expressing PC-3 cells were isolated after culturing those transfectants in the medium containing 10% FCS, they must have been able to grow in the presence of 10% FCS (see time-lapse microscopy experiments below).

¹ IGF-I protein levels secreted into conditioned media by parental and PC-3 cell transfectants were determined. The IGF-I levels measured, however, were too low to be informative given that PC-3 cell IGF-I levels are below accurate levels of detection (22).

IGF-II AND CELL GROWTH MODULATION BY RIBOZYMES

A. Ribozyme (R) expression



B. IGF-II mRNA levels




FIG. 7. Expression of RZ under the control of Pol II promoter. A, Detection of RZ expression by RT-PCR. Experiments were performed as described in Fig. 6A. B, Endogenous IGF-II mRNA levels in parental PC-3 cells, R-expressing PC-3 cells, and vector-controls as determined by QC-PCR. Experiments were performed as described in Fig. 6B. C, IGF-II protein levels in conditioned media. IGF-II protein levels in conditioned media harvested from parental cells and PC-3 cell transfectants were measured in duplicate.

Effect of RZ expression on PC-3 cell growth as measured by time-lapse microscopy. Analysis of cell division of parental PC-3 cells, vector-transfected cells (V37), and R-expressing PC-3 cells (R4, R6, and R39) revealed doubling times (mean \pm SEM) of 28.3 ± 0.39 (n = 8), 32.3 ± 1.0 (n = 3), 37 ± 1.1 (n = 6), 38.6 ± 2.3 (n = 5), and 42.5 ± 2.8 (n = 2) h, respectively (Table 3). This result indicates that PC-3 cells expressing the IGF-II RZ showed a significantly prolonged doubling times compared with parental PC-3 cells, while the doubling times of vector-transfected PC-3 cells are not significantly different from those of the parental cells.

Discussion

Hammerhead RZs against human IGF-II RNA, which we have constructed, were catalytically active *in vitro*. The catalytic efficiencies, however, varied among differently designed IGF-II RZs. The results can be summarized as follows; $RR > R \sim RM > MR$. This indicates that the first RZ cleavage site may be a better target than the second RZ cleavage site since the cleavage of the former by R, RM, or RR was more

TABLE 2. IGF-II protein levels secreted into conditioned media

	Exp	IGF-II protein level (ng/ml/10 ⁵ cells)
Parental PC-3 cells	1	6.22
	2	5.85
Vector-transfected PC-3 cells	1	4.07
	2	4.5
R-expressing PC-3 cells (R3)	1	2.07
	2	2.91
R-expressing PC-3 cells (R4)	1	2.95
	2	2.5
R-expressing PC-3 cells (R6)	1	2.31
	2	2.06
R-expressing PC-3 cells (R39)	1	1.07
	2	3.68

IGF-II protein levels in conditioned media harvested from parental PC-3 cells and transfectants were measured in duplicate. IGF-II protein levels in the pooled data of R-expressing PC-3 cells were significantly different ($P < 0.01$) by Newman-Keuls post hoc test compared with parental and vector-transfected PC-3 cells.

efficient than that of the later by MR. Of three double RZs examined, RR was more active than RM and MR. RR was also 3-fold more efficient in cleaving a substrate IGF-II RNA than R as judged by kinetic analysis under single-turnover conditions. Both RM and R were equally active despite the difference in the length of antisense arms, 29 and 17 nt, respectively. These results suggest that the tandem repeat of two catalytic domains enhances the catalytic efficiency of the RZ rather than the longer antisense arms. When a longer RNA substrate was used, RR was much more effective in cleaving the substrate than R. However, the cleavage of the longer substrate (1157 nt) required a much higher concentration of RR than that of the shorter substrate (147 nt). These observations are generally in good agreement with the results of previous studies that systematically analyzed the effects of catalytic core tandem repeats (42) or antisense arm lengths on RZ cleavage reactions *in vitro* (43).

Single and double RZs were stably expressed in human prostate cancer PC-3 cells under the control of RNA pol III or pol II promoter. Stable transfectants were isolated and used to determine the efficacy of the RZ activity in cells and effects of active RZs on cell growth. Establishment of quantitative assays for the target RNA was necessary for the detection of RZ cleavage reactions *in vivo* (in cell line). The QC-PCR method was used in this study because it is very sensitive, specific, and quantitative (44). In contrast to most of the RT-PCR methods that use two pairs of primers, the competitor IGF-II RNA shares the same sequences for primer binding as the target endogenous IGF-II mRNA. But, it contains an additional 110-base long insert that will give a PCR product larger than the PCR product generated from the target endogenous IGF-II mRNA. This 110-base difference in size was sufficient for easy separation of the two PCR products on denaturing polyacrylamide gels and for quantitation of the radioactive bands with a PhosphorImager (Fig. 6A). Using QC-PCR, we have clearly demonstrated that the intracellularly expressed RZs cleaved endogenous IGF-II mRNA.

Interestingly, in our study, single and double RZs showed almost the same level of efficacy in reduction of IGF-II mRNA in PC-3 cells. This observation can be explained in the fol-

IGF-II AND CELL GROWTH MODULATION BY RIBOZYMES


Endo • 1999
Vol 140 • No 5

FIG. 8. Effect of RZ expression on PC-3 cell growth as measured by the MTT method. Cell growth under serum-free conditions (A) or in the presence of 2% FCS (B). Parental PC-3 cells (⊕), vector-control PC-3 cells (V37; □), R-expressing PC-3 cells (R4; ◇, R6; ○, and R39; △) were cultured either in serum-free medium (SFM) or in the presence of 2% FCS. Cell growth was determined for 4 days in triplicate by the MTT method. Growth curves are normalized by setting the OD value of day 1 as 100% for each transfectant. Shown are the representative results from three independent experiments.

TABLE 3. Effect of RZ expression on PC-3 cell growth as measured by time-lapse microscopy

	PC-3 cells	R-expressing transfectants			Vector transfectant V37
		R4	R6	R39	
Doubling time \pm SEM (h)	28.3 \pm 0.39	37 \pm 1.1	38.6 \pm 2.3	42.5 \pm 2.8	32.3 \pm 1.0
Doubling time (-fold) relative to parental PC-3 cells	1.00	1.31	1.36	1.50	1.14
		$P < 0.01$	$P < 0.001$	$P < 0.001$	$P > 0.05$

Cell division of parental PC-3 cells and transfectants in RPMI1640 in the presence of 10% FCS was recorded. Doubling time for each clone was calculated from five to eight divisions.

lowing ways: 1) due to unique secondary or tertiary structure caused by other cellular factors, interaction of IGF-II mRNA with the double RZ may make one of the cleavage domains unable to anneal with the substrate (second cleavage site); thus there is no cleavage reaction for that domain; or 2) the RZ-expressing clones selected may be only those that are able to moderately reduce IGF-II to a point that does not cause cell death.

Although *in vitro* studies of RZs are essential steps for quantitating their catalytic efficiencies, they cannot be used to predict the efficiency of the RZs when expressed in cells. Due to the complexity of eukaryotic gene expression, and also multiple factors involved, the RZ action in the cell is heavily influenced by the cellular environment. Factors that may interfere with RZ action in the cell include RZ expression level, colocalization of RZs with the target RNAs, location of the RZ gene relative to the target gene in the host genome, target sites at which the RZ functions, secondary structure of the target RNA or RZs, and cofactors or inhibitors such as proteins, Mg^{2+} concentration, and pH. For example, if RZ expression is not highly efficient, the level of RZs may be too low to cleave the target RNA. Even though RZs are efficiently expressed, if RZs are not in the same cell

compartment with the target RNA, RZ activity would be dramatically decreased.

The secondary structure of the target RNA or RZs is also very important. Since RZs cleave the target RNA by first complementary binding to the target RNA, if the secondary structure of target RNA or RZs interferes with the binding of RZ and target, RZ activity will be reduced. Also, proteins may bind to portions of the RNA substrate or to the RZ itself and may facilitate or interfere with the catalysis. For example, previous studies demonstrated an enhancement of RZ cleavage reactions by RNA-binding proteins such as heterogeneous nuclear ribonucleoprotein A1 and the capsid protein NC7 of human immunodeficiency virus type 1 (HIV-1) (37, 45, 46). In our study, pTZU6 + 27 and pcDNA 3 vectors were used to express IGF-II RZs intracellularly under the control of RNA pol III and II, respectively. The RZ transcripts from pTZU6+27/RZ should be relatively stable and expressed in both nucleus and cytoplasm, but mainly in the nucleus (36, 47, 48). Pol III promoters, which naturally drive transfer RNA and small nuclear RNA synthesis, are good for high-level, non-tissue-specific expression of short RNAs. For example, Thompson *et al.* (41) used a transfer RNA-based RNA pol III promoter-driven RZ and found high accumulation of recom-

IGF-II AND CELL GROWTH MODULATION BY RIBOZYMES

binant pol III RZ transcripts in all cell lines tested. The RZ activity was readily detectable in total RNA extracted from stably transformed human T cell lines. Michienzi *et al.* (48) used U1 small nuclear RNA chimeric RZs with substrate specificity for the Rev pre-mRNA of HIV and showed that this construct caused more efficient reduction in the Rev pre-mRNA level *in vivo*. Kawasaki *et al.* (49) reported that by using a pol III-driven vector, the adenoviral-E1A-associated 300-kDa protein expression in HeLa cells was inhibited. In contrast, the RZ transcripts from pcDNA3/RZ can be ubiquitously expressed in the cytoplasm under the control of RNA pol II. Pol II promoters, including viral promoters, which are used naturally for mRNA synthesis, can allow tissue-specific expression of RZs. A disadvantage of Pol II promoters is their requirement for long coding sequences, so that the RZ sequence may be placed in long RNA molecules. This can interfere with RZ conformation.

In the present study, both pol II and pol III promoter-driven vectors similarly expressed RZs and suppressed IGF-II mRNA levels in PC-3 cells, which resulted in cell growth inhibition. It should be noted that the growth of M-expressing PC-3 cells was not affected although the M RZ could have an antisense effect. Since the *in vitro* experiments revealed formation of a stable IGF-II RNA substrate/M RZ as seen in Fig. 2, formation of the complex in cells might also take place. Our results, however, indicate that if such a complex formed in PC-3 cells, it was not sufficiently stable to inhibit cell growth. It is possible that short RNA hybrids may be destroyed by ribosome translocation or heterogeneous nuclear ribonucleoproteins (37). The different results in the growth effects observed between R and M RZs thus support the notion that the catalytic activity of R RZ is required to significantly inhibit cell growth under our experimental conditions.

Suppression of IGF-II mRNA levels by the RZs was associated with reduced IGF-II protein levels. The reduction of protein levels was, however, not as significant as that of mRNA levels. This suggests that there may be a possible difference in the regulation of two IGF-II forms, the regular 7.5-kDa form and the incompletely processed 15-kDa form. The IGF-II protein levels measured in this study reflect those of both 7.5- and 15-kDa IGF-II since the RIA used an anti-IGF-II antibody that binds both forms of IGF-II. It is possible that the expression of the 15-kDa IGF-II, which is commonly expressed in cancerous tissues, is more affected by IGF-II RZ actions while the 7.5-kDa IGF-II level may not be affected. Further analysis of the expressed IGF-II protein by immunoblotting is necessary to substantiate this possibility. It is also necessary to examine whether expression of other IGF system components including IGF-binding proteins has been changed when an active RZ is intracellularly expressed.

RZ-expressing PC-3 cells did not grow well but rather die under serum-starved conditions while they grew in the medium supplemented by 10% FCS, which was the condition used for isolation of the RZ-expressing clones. It has been shown that PC-3 cells undergo apoptosis under serum-free conditions (50), and that IGFs are antiapoptotic (15–17). Consistent with those previous studies, the results shown in Fig. 8 show that PC-3 cell and vector-control cells seem to undergo apoptosis in SFM, and that the reduction of IGF-II

levels by intracellular expression of IGF-II RZs seem to stimulate apoptosis of PC-3 cells in SFM and low serum medium. Investigation on mitogenic and apoptotic pathways of R-expressing PC-3 cells are now in progress.

In conclusion, the present study demonstrated that IGF-II RZs were active at least in one cell line and were able to lower endogenous IGF-II mRNA and protein levels, and that blockage of IGF-II/IGFIR signaling by IGF-II RZs inhibited cell growth. The IGF-II RZ can thus be used as a tool to investigate the role of IGF-II in other physiological systems. The study also provided the basis for the development of IGF-II RZs as future cancer therapeutics.

References

1. Daughaday WH 1990 The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. *Endocrinology* 127:1–4
2. LeRoith D, Werner H, Beitner-Johnson D, Roberts Jr CT 1995 Molecular and cellular aspects of the insulin-like growth factor I receptor. *Endocr Rev* 16:143–163
3. Casella SJ, Han VK, D'Ercole AJ, Svoboda ME, van Wyk JJ 1986 Insulin-like growth factor II binding to the type I somatomedin receptor. Evidence for two high affinity binding sites. *J Biol Chem* 261:9268–9273
4. Sakano K, Enjoh T, Numata F, Fujiwara H, Marumoto Y, Higashihashi N, Sato Y, Perdue JF, Fujita-Yamaguchi Y 1991 The design, expression, and characterization of human insulin-like growth factor II (IGF-II) mutants specific for either the IGF-II/cation-independent mannose 6-phosphate receptor or IGF-I receptor. *J Biol Chem* 266:20626–20635
5. Bach LA, Hsieh S, Sakano K, Fujiwara H, Perdue JF, Rechler MM 1993 Binding of mutant of human insulin-like growth factor II to insulin-like growth factor binding proteins 1–6. *J Biol Chem* 268:9246–9254
6. Daughaday W, Rotwein P 1989 Insulin-like growth factors 1 and 2, peptide messenger ribonucleic acid, gene structures and serum and tissue concentrations. *Endocr Rev* 10:68–91
7. Daughaday WH, Trivedi B 1992 Measurement of derivative of proinsulin-like growth factor-II in serum by a radioimmunoassay directed against the E-domain in normal subjects and patients with nonislet cell tumor hypoglycemia. *J Clin Endocrinol Metab* 75:110–115
8. Enjoh T, Hizuka N, Perdue JF, Takano K, Fujiwara H, Higashihashi N, Marumoto Y, Fukuda I, Sakano K 1993 Characterization of new monoclonal antibodies to human insulin-like growth factor-II and their application in Western immunoblot analysis. *J Clin Endocrinol Metab* 77:510–517
9. Li SL, Goko H, Xu ZD, Kimura G, Sun Y, Kawachi MH, Wilson TG, Wilczynski S, Fujita-Yamaguchi Y 1998 Expression of insulin-like growth factor (IGF)-II in human prostate, breast, bladder, and paraganglioma tumors. *Cell Tissue Res* 291:469–479
10. Gowan LK, Hampton B, Hill JD, Shlueter RI, Perdue JF 1987 Purification and characterization of a unique high molecular weight form of insulin-like growth factor II. *Endocrinology* 121:449–458
11. Baserga R 1995 The insulin-like growth factor-1 receptor: a key to tumor growth? *Cancer Res* 55:249–252
12. Werner H, LeRoith D 1997 The insulin-like growth factor-I receptor signaling pathways are important for tumorigenesis and inhibition of apoptosis. *Crit Rev Oncog* 8:71–92
13. Kaleko M, Rutter WG, Miller AD 1990 Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. *Mol Cell Biol* 10:464–473
14. Prager D, Li H-L, Asa S, Melmed S 1994 Dominant negative inhibition of tumorigenesis *in vivo* by human insulin-like growth factor I receptor mutant. *Proc Natl Acad Sci USA* 91:2181–2185
15. Harrington EA, Bennett MR, Fanidi A, Evan GI 1994 c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. *EMBO J* 13:3286–3295
16. Resnicoff M, Abraham D, Yutanawiboonchai W, Rotman HL, Kajstura J, Rubin R, Zoltick P, Baserga R 1995 The insulin-like growth factor I receptor protects tumor cells from apoptosis *in vivo*. *Cancer Res* 55:2463–2469
17. Sell C, Baserga R, Rubin R 1995 Insulin-like growth factor (IGF-1) and the IGF-1 receptor prevent etoposide-induced apoptosis. *Cancer Res* 55:303–306
18. Dunn SE, Hardman RA, Kari FW, Barrett JC 1997 Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. *Cancer Res* 57:2687–2693
19. Pietrzowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R 1993 Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor I. *Cancer Res* 53:1102–1106
20. Figueroa JA, Lee AV, Jackson J, Yee D 1995 Proliferation of cultured human prostate cancer cells is inhibited by insulin-like growth factor (IGF) binding

IGF-II AND CELL GROWTH MODULATION BY RIBOZYMES

Endo • 1999
Vol 140 • No 5

- protein-1: evidence for an IGF-II autocrine growth loop. *J Clin Endocrinol Metab* 80:3476-3482
21. Angeloz-Nicoud P, Binoux M 1995 Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). *Endocrinology* 136:5485-5492
22. Kimura G, Kasuya J, Giannini S, Honda Y, Mohan S, Kawachi MH, Akimoto M, Fujita-Yamaguchi Y 1996 Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. *Int J Urol* 3:39-46
23. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate SR 1996 Protein and messenger ribonucleic acid (mRNA) for the type I insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. *J Clin Endocrinol Metab* 81:3774-3782
24. Christofori G, Naik P, Hanahan D 1994 A second signal supplied by insulin-like growth factor II in oncogene-induced tumorigenesis. *Nature* 369:414-418
25. Florini JR, Magri KA, Ewton DZ, James PL, Grindstaff K, Rotwein PS 1991 "Spontaneous" differentiation of skeletal myoblasts is dependent upon autocrine secretion of insulin-like growth factor-II. *J Biol Chem* 266:15917-15923
26. Lin S-B, Hsieh S-H, Hsu H-L, Lai M-Y, Kan L-S, Au L-C 1997 Antisense oligodeoxynucleotides of IGF-II selectively inhibit growth of human hepatoma cells overproducing IGF-II. *J Biochem (Tokyo)* 122:717-722
27. Neuenschwander S, Roberts Jr CT, LeRoith D 1995 Growth inhibition of MCF-7 breast cancer cells by stable expression of an insulin-like growth factor I receptor antisense ribonucleic acid. *Endocrinology* 136:4298-4303
28. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R 1994 Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. *Cancer Res* 54:4848-4850
29. Osborne CK, Coronado EB, Kitten LJ, Arteaga CI, Fuqua SAW, Rasmahartha K, Marchall M, Li CH 1989 Insulin-like growth factor-II (IGF-II): a potential autocrine/paracrine growth factor for human breast cancer acting via the IGF-I receptor. *Mol Endocrinol* 3:1701-1709
30. Furlanetto RW, Harwell SE, Baggs RB 1993 Effects of insulin-like growth factor receptor inhibition on human melanomas in culture and in athymic mice. *Cancer Res* 53:2522-2526
31. Damon SE, Maddison L, Ware JL, Plymate SR 1998 Overexpression of an inhibitory insulin-like growth factor binding protein (IGFBP), IGFBP-4, delays onset of prostate tumor formation. *Endocrinology* 139:3456-3464
32. Miglietta L, Barreca A, Reppetto L, Constantini M, Rosso R, Boccardo F 1993 Suramin and serum insulin-like growth factor levels in metastatic cancer patients. *Anticancer Res* 13:2473-2476
33. Guvakova MA, Surmacz E 1997 Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. *Cancer Res* 57:2606-2610
34. Rossi JJ 1998 Therapeutic ribozymes, principles and applications. *BioDrugs* 9:1-10
35. Bell GI, Merryweather JP, Sanchez-Pescador R, Stempien MM, Priestley L, Scott J, Rall LB 1984 Sequence of a cDNA clone encoding human preproinsulin-like growth factor II. *Nature* 310:775-779
36. Good PD, Krikos AJ, Li SX, Bertrand E, Lee NS, Giver L, Ellington A, Zaia JA, Rossi JJ, Engelke DR 1997 Expression of small, therapeutic RNAs in human cell nuclei. *Gene Ther* 4:45-54
37. Bertrand EL, Rossi JJ 1994 Facilitation of hammerhead ribozyme catalysis by the nucleocapsid protein of HIV-1 and the heterogeneous nuclear ribonucleoprotein A1. *EMBO J* 13:2904-2912
38. Hertel KJ, Herschlag D, Ulenbeck OC 1994 A kinetic and thermodynamic framework for the hammerhead ribozyme reaction. *Biochemistry* 33:3373-3385
39. Heidenreich O, Eckstein F 1992 Hammerhead ribozyme-mediated cleavage of the long terminal repeat RNA of human immunodeficiency virus type 1. *J Biol Chem* 267:1904-1909
40. Chen C, Okayama H 1987 High-efficiency transformation of mammalian cells by plasmid DNA. *Mol Cell Biol* 7:2745-2752
41. Thompson JD, Ayers DF, Malmstrom TA, McKenzie TL, Ganousis L, Chworira BM, Couture L, Stinchcomb DT 1995 Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. *Nucleic Acids Res* 23:2259-2268
42. Ohkawa J, Yuyama N, Takebe Y, Nishikawa S, Taira K 1993 Importance of independence in ribozyme reactions: kinetic behavior of trimmed and of simply connected multiple ribozymes with potential activity against human immunodeficiency virus. *Proc Natl Acad Sci USA* 90:11302-11306
43. Sioud M 1997 Effects of variations in length of hammerhead ribozyme antisense arms upon the cleavage of longer RNA substrates. *Nucleic Acids Res* 25:333-338
44. Beaudry AA, McSwiggen JA 1995 Quantitation of ribozyme target abundance by QPCR. *Methods Mol Biol* 74:1357-1364
45. Tsuchihashi Z, Kholsa M, Herschlag D 1993 Protein enhancement of hammerhead ribozyme catalysis. *Science* 262:99-102
46. Herschlag D, Kholsa M, Tsuchihashi Z, Karpel RL 1994 An RNA chaperone activity of non-specific RNA binding proteins in hammerhead ribozyme catalysis. *EMBO J* 13:2913-2924
47. Bertrand E, Castanotto D, Zhou C, Cambonelle C, Lee NS, Good P, Chatterjee S, Grange T, Pictet R, Kohn D, Engelke D, Rossi JJ 1997 The expression cassette determines the functional activity of ribozymes in mammalian cells by controlling their intracellular localization. *RNA* 3:75-88
48. Michienzi A, Prislei S, Bozzoni I 1996 U1 small nuclear RNA chimeric ribozymes with substrate specificity for the Rev pre-mRNA of human immunodeficiency virus. *Proc Natl Acad Sci USA* 93:7219-7224
49. Kawasaki H, Ohkawa J, Tanishige N, Yoshinari K, Murata T, Yokoyama K, Taira K 1996 Selection of the best target site for ribozyme-mediated cleavage within a fusion gene for adenovirus E1A-associated 300 kDa protein (p300) and luciferase. *Nucleic Acids Res* 24:3010-3016
50. Rajah R, Valentinis B, Cohen P 1997 Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor beta1 on programmed cell death through a p53- and IGF-independent mechanism. *J Biol Chem* 272:12181-12188